Atlas Trials

Taiho Oncology, Inc.

66 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Taiho Oncology, Inc.

RecordFirmDate
A Study of ARC-02 in B-cell NHL (NCT07691606)Taiho Oncology, Inc.2026-06-22
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection (NCT07128199)Taiho Oncology, Inc.2025-12-22
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. (NCT06506955)Taiho Oncology, Inc.2024-10-01
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (NCT05967689)Taiho Oncology, Inc.2023-07-31
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (NCT05945823)Taiho Oncology, Inc.2023-07-13
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (NCT05727176)Taiho Oncology, Inc.2023-07-05
A Study of TAS3351 in NSCLC Patients With EGFRmt (NCT05765734)Taiho Oncology, Inc.2023-05-25
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) (NCT05403450)Taiho Oncology, Inc.2023-02-22
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment (NCT04953910)Taiho Oncology, Inc.2022-12-23
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment (NCT04953897)Taiho Oncology, Inc.2021-12-15
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer (NCT04965818)Taiho Oncology, Inc.2021-09-20
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer (NCT04982926)Taiho Oncology, Inc.2021-09-16
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations (NCT04770246)Taiho Oncology, Inc.2021-03-31
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) (NCT04657081)Taiho Oncology, Inc.2021-02-09
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma (NCT04601857)Taiho Oncology, Inc.2021-01-07
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (NCT04093362)Taiho Oncology, Inc.2021-01-06
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients (NCT04737187)Taiho Oncology, Inc.2020-11-25
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer (NCT04586270)Taiho Oncology, Inc.2020-10-15
Futibatinib in Patients With Specific FGFR Aberrations (NCT04189445)Taiho Oncology, Inc.2020-08-05
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) (NCT04256317)Taiho Oncology, Inc.2020-05-21
A Study of TAS-120 in Patients With Metastatic Breast Cancer (NCT04024436)Taiho Oncology, Inc.2020-01-28
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) (NCT04093570)Taiho Oncology, Inc.2019-09-30
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (NCT03975387)Taiho Oncology, Inc.2019-07-11
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS (NCT03502668)Taiho Oncology, Inc.2018-07-27
Study of ASTX029 in Subjects With Advanced Solid Tumors (NCT03520075)Taiho Oncology, Inc.2018-05-07
A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities (NCT03410927)Taiho Oncology, Inc.2018-04-06

Track Taiho Oncology, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.